CDD-1274 

CDD-1274 is an ERα (Estrogen receptor α) variant inhibitor. CDD-1274 induces proteasomal degradation of ERα variants in breast cancer cell lines and causes Y537S ERα degradation. CDD-1274 potently blocks ligand-dependent and ligand-independent ER signaling in endocrine-resistant breast cancer cells. CDD-1274 can be used for the study of breast cancer^[1].

CDD-1274 (10 μM) effectively blocks the recruitment of SRC3 coactivator peptides to Y537S and D538G mutant ERa LBDs^[1].
CDD-1274 (0-10 μM, 0-48 h) reduces the levels of WT and Y537S ERa proteins in T47D parental and T47D Y537S, accompanied by decreased expression of cyclin D1, survivin, and progesterone receptor (PR)^[1].
CDD-1274 (10 μM, 24 h) reduces ERa protein levels in MCF-7 parental and MCF-7 Y537S and D538G mutants; decreases the expression of cell proliferation markers (cyclin D1, survivin, E2F1) and ER target genes (TFF1, GREB1, PR); and increases the apoptosis marker c-PARP^[1].
CDD-1274 (10 μM, 24 h) degrades WT and Y537S ERa in Palbociclib-resistant MCF-7 WT and Y537S cells and inhibits the expression of cyclin D1, survivin, and TFF1^[1].
CDD-1274 (10 μM, 24 h) reduces ERa and proliferation markers in ER-positive cells (such as T47D and MCF-7); in ER-negative cells (MCF-10A, HCC1954, MDA-MB-231, and VCaP), it was a pure antagonist in Ishikawa^[1].
CDD-1274 (10 μM, 24 h) induces persistent ERa degradation in T47D parental and T47D Y537S^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

567.57

C₂₈H₃₃F₄N₃O₅

O=C(NC)CCOCCC(N1CC(C2NCC3=CC(C4=CC(O)=CC=C4OC(F)(F)F)=CC=C3F)CCC2C1)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Devakrishnan AK, et al. Discovery of a novel small molecule degrader of wild type and mutant estrogen receptors using DNA encoded libraries. NPJ Breast Cancer. 2025 Nov 12;11(1):125.  [Content Brief]